Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

Gomez J, Suarez A, Lopez P, Mozo L, Diaz JB, Gutierrez C: Systemic lupus erythematosus in Asturias, Spain: clinical and serologic features. Medicine (Baltimore) 85(3), 157-168 (2006). Antolin J ...

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Background SLE is a systemic autoimmune disease with a large number of common risk gene variants, but several rare gene ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...

Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE). Credit: MirageC via Getty Images. Roche’s subsidiary Genentech has shared positive Phase III data with ...

Researchers at Washington University School of Medicine in St. Louis have conducted a longitudinal study on an individual ...